Akebia Therapeutics (AKBA) Misses Q3 EPS by 4c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.10), $0.04 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $37.43 million versus the consensus estimate of $44.5 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Laser Photonics regains NASDAQ compliance after filing quarterly report